

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED

北京同仁堂國藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3613)

VOLUNTARY ANNOUNCEMENT

RECEIVING THE TRADITIONAL MEDICINE REGISTRATION LICENSE

This announcement is made by the board of directors (the “**Board**”) of Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) on a voluntary basis to inform its shareholders and potential investors of the latest business development about the Company.

The Board is pleased to announce that the Company recently received the tradition medicine registration license (the “**License**”) issued by the Department of Drugs and Food of the Ministry of Health of the Kingdom of Cambodia (“**Cambodia**”), allowing “Tong Ren Tang Angong Niu Huang Wan” of the Company to be sold in Cambodia. The relevant details are as follows:

I. Basic Information of the Medicine

Name of the medicine: Tong Ren Tang Angong Niu Huang Wan

Name and address of the License holder: Beijing Tong Ren Tang Chinese Medicine Company Limited, Room 1405-1409, 14/F, Office Tower, Convention Plaza, 1 Harbour Road, Wanchai, Hong Kong, China

License number: CAM N0004IT-25

License validity period: Until 11 September 2028

II. Other Related Information of the Medicine

The “Tong Ren Tang Angong Niu Huang Wan” should be used under the supervision of a licensed traditional Chinese medicine practitioner. Additionally, the import license for “Tong Ren Tang Angong Niu Huang Wan” had been issued by the Ministry of Health of Cambodia previously.

III. Impact on the Company and Risk Warning

Upon obtaining the License issued by the Department of Drugs and Food of the Ministry of Health of Cambodia, “Tong Ren Tang Angong Niu Huang Wan” of the Company can be sold in Cambodia, which is conducive to expanding the distribution channels of the Company’s major products and beneficial to the market expansion of the Company. The obtaining of the License will not have any material impact on the production, operation and performance of the Company for the time being. The sales of pharmaceutical products can be influenced by factors such as change in the policy environment, exchange rate fluctuations and market competition in Cambodia.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
Beijing Tong Ren Tang
Chinese Medicine Company Limited
Yan Han
Chairman

Hong Kong, 26 September 2025

As at the date of this announcement, the composition of the Board is as follows:

Executive Directors:

Mr. Yan Han (*Chairman*)
Mr. Yue Zheng (*Vice Chairman*)
Mr. Wang Chi

Independent Non-executive Directors:

Mr. Tsang Yok Sing, Jasper
Mr. Xu Hong Xi
Mr. Chan Ngai Chi

Non-executive Director:

Ms. Feng Li